About: Dual effect of nitric oxide on SARS-CoV replication: Viral RNA production and palmitoylation of the S protein are affected

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Dual effect of nitric oxide on SARS-CoV replication: Viral RNA production and palmitoylation of the S protein are affected Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Dual effect of nitric oxide on SARS-CoV replication: Viral RNA production and palmitoylation of the S protein are affected
Creator	Tan, Yee-Joo Mirazimi, Ali Gunalan, Vithiagaran Keng, Choong
Source	Elsevier; Medline; PMC
abstract	Abstract Nitric oxide is an important molecule playing a key role in a broad range of biological process such as neurotransmission, vasodilatation and immune responses. While the anti-microbiological properties of nitric oxide-derived reactive nitrogen intermediates (RNI) such as peroxynitrite, are known, the mechanism of these effects are as yet poorly studied. Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) belongs to the family Coronaviridae, was first identified during 2002-2003. Mortality in SARS patients ranges from between 6 to 55%. We have previously shown that nitric oxide inhibits the replication cycle of SARS-CoV in vitro by an unknown mechanism. In this study, we have further investigated the mechanism of the inhibition process of nitric oxide against SARS-CoV. We found that peroxynitrite, an intermediate product of nitric oxide in solution formed by the reaction of NO with superoxide, has no effect on the replication cycle of SARS-CoV, suggesting that the inhibition is either directly effected by NO or a derivative other than peroxynitrite. Most interestingly, we found that NO inhibits the replication of SARS-CoV by two distinct mechanisms. Firstly, NO or its derivatives cause a reduction in the palmitoylation of nascently expressed spike (S) protein which affects the fusion between the S protein and its cognate receptor, angiotensin converting enzyme 2. Secondly, NO or its derivatives cause a reduction in viral RNA production in the early steps of viral replication, and this could possibly be due to an effect on one or both of the cysteine proteases encoded in Orf1a of SARS-CoV.
has issue date	2009-12-05(xsd:dateTime)
bibo:doi	10.1016/j.virol.2009.09.007
bibo:pmid	19800091
has license	els-covid
sha1sum (hex)	d081f552145f323c7a81808f5f61bca4ce2b9cff
schema:url	https://doi.org/10.1016/j.virol.2009.09.007
resource representing a document's title	Dual effect of nitric oxide on SARS-CoV replication: Viral RNA production and palmitoylation of the S protein are affected
has PubMed Central identifier	PMC7111989
has PubMed identifier	19800091
schema:publication	Virology
resource representing a document's body	covid:d081f552145f323c7a81808f5f61bca4ce2b9cff#body_text
is schema:about of	named entity 'mechanisms' named entity 'neurotransmission' named entity 'protein' covid:arg/d081f552145f323c7a81808f5f61bca4ce2b9cff named entity 'ranges' named entity 'mechanism' named entity 'effected' named entity 'inhibition' named entity 'viral replication' named entity 'process' named entity 'reduction' named entity 'family' named entity 'study' named entity 'replication cycle' named entity '2003' named entity 'inhibition' named entity 'investigated' named entity 'SARS-CoV' named entity 'derivatives' named entity 'production' named entity 'key' named entity 'angiotensin converting enzyme 2' named entity 'replication cycle' named entity 'nitric oxide' named entity 'SARS-CoV' named entity 'peroxynitrite' named entity 'SARS-CoV' named entity 'peroxynitrite' named entity 'Severe Acute Respiratory Syndrome coronavirus' named entity 'SARS-CoV' named entity 'Nitric oxide' named entity 'Viral' named entity '96-well plate' named entity 'Western blot' named entity 'protein' named entity 'SARS-CoV' named entity 'incubation' named entity 'protein' named entity 'transfected' named entity 'Tecan' named entity 'viruses' named entity 'ACE2 receptor' named entity 'ACE2' named entity 'S protein' named entity 'incubation' named entity 'Vaccine' named entity 'infection' named entity 'protein' named entity 'Nitric oxide' named entity 'primer pairs' named entity 'SARS-CoV' named entity 'protein' named entity 'superoxide' named entity 'virus replication' named entity 'cell fusion' named entity 'cysteine' named entity 'HIV' named entity 'positive-sense RNA' named entity 'protein binding' named entity 'polyclonal antibody' named entity 'SARS-CoV' named entity 'cell culture' named entity 'infectivity' named entity 'Invitrogen' named entity 'virus' named entity 'protein' named entity 'palmitoylation' named entity 'vector' named entity 'protein' named entity 'cysteine proteases' named entity 'peroxynitrite' named entity 'micro-organisms' named entity 'infection' named entity 'incubation' named entity 'reverse transcribed' named entity '3C-like protease' named entity 'quencher' named entity 'nucleocapsid'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software